Showing 64,601 - 64,620 results of 67,168 for search '(( e non decrease ) OR ( 5 ((((point decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 0.97s Refine Results
  1. 64601
  2. 64602
  3. 64603
  4. 64604
  5. 64605
  6. 64606
  7. 64607
  8. 64608

    Image_1_Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recove... by Bernardo L. Rapoport (7431842)

    Published 2023
    “…Relative to a group of healthy control subjects (n=45), the median pre-treatment levels of five co-stimulatory (CD27, CD40, GITRL, ICOS, GITR) and three co-inhibitory (TIM-3, CTLA-4, PD-L1) soluble checkpoints were significantly lower in the BC patients vs. controls (p<0.021-p<0.0001; and p<0.008-p<0.00001, respectively). …”
  9. 64609

    Image_2_Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recove... by Bernardo L. Rapoport (7431842)

    Published 2023
    “…Relative to a group of healthy control subjects (n=45), the median pre-treatment levels of five co-stimulatory (CD27, CD40, GITRL, ICOS, GITR) and three co-inhibitory (TIM-3, CTLA-4, PD-L1) soluble checkpoints were significantly lower in the BC patients vs. controls (p<0.021-p<0.0001; and p<0.008-p<0.00001, respectively). …”
  10. 64610

    Image_3_Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recove... by Bernardo L. Rapoport (7431842)

    Published 2023
    “…Relative to a group of healthy control subjects (n=45), the median pre-treatment levels of five co-stimulatory (CD27, CD40, GITRL, ICOS, GITR) and three co-inhibitory (TIM-3, CTLA-4, PD-L1) soluble checkpoints were significantly lower in the BC patients vs. controls (p<0.021-p<0.0001; and p<0.008-p<0.00001, respectively). …”
  11. 64611

    Table_1_SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.docx by Haiying Fu (1285074)

    Published 2021
    “…SEPT6_TRIM33 gene fusion, mutated TP53 and Hippo pathways were significantly associated with poor PFS, and SEPT6_TRIM33 fusion gene and mutated TP53 pathway were independent prognostic factors for B-cell lymphoma. A decreased VAF of TP53 p.Y88C and LATS2 p.F972L was detected in patients with complete response to treatments. …”
  12. 64612

    Image_3_SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.tif by Haiying Fu (1285074)

    Published 2021
    “…SEPT6_TRIM33 gene fusion, mutated TP53 and Hippo pathways were significantly associated with poor PFS, and SEPT6_TRIM33 fusion gene and mutated TP53 pathway were independent prognostic factors for B-cell lymphoma. A decreased VAF of TP53 p.Y88C and LATS2 p.F972L was detected in patients with complete response to treatments. …”
  13. 64613

    Data_Sheet_2_CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients.docx by Anouk von Borstel (7421039)

    Published 2019
    “…</p><p>Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1–6.3). …”
  14. 64614

    Table_1_CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients.docx by Anouk von Borstel (7421039)

    Published 2019
    “…</p><p>Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1–6.3). …”
  15. 64615

    Image_2_SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.tif by Haiying Fu (1285074)

    Published 2021
    “…SEPT6_TRIM33 gene fusion, mutated TP53 and Hippo pathways were significantly associated with poor PFS, and SEPT6_TRIM33 fusion gene and mutated TP53 pathway were independent prognostic factors for B-cell lymphoma. A decreased VAF of TP53 p.Y88C and LATS2 p.F972L was detected in patients with complete response to treatments. …”
  16. 64616

    Image_4_Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recove... by Bernardo L. Rapoport (7431842)

    Published 2023
    “…Relative to a group of healthy control subjects (n=45), the median pre-treatment levels of five co-stimulatory (CD27, CD40, GITRL, ICOS, GITR) and three co-inhibitory (TIM-3, CTLA-4, PD-L1) soluble checkpoints were significantly lower in the BC patients vs. controls (p<0.021-p<0.0001; and p<0.008-p<0.00001, respectively). …”
  17. 64617

    Data_Sheet_1_CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients.docx by Anouk von Borstel (7421039)

    Published 2019
    “…</p><p>Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1–6.3). …”
  18. 64618

    Image_1_SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.tif by Haiying Fu (1285074)

    Published 2021
    “…SEPT6_TRIM33 gene fusion, mutated TP53 and Hippo pathways were significantly associated with poor PFS, and SEPT6_TRIM33 fusion gene and mutated TP53 pathway were independent prognostic factors for B-cell lymphoma. A decreased VAF of TP53 p.Y88C and LATS2 p.F972L was detected in patients with complete response to treatments. …”
  19. 64619

    Image_6_Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recove... by Bernardo L. Rapoport (7431842)

    Published 2023
    “…Relative to a group of healthy control subjects (n=45), the median pre-treatment levels of five co-stimulatory (CD27, CD40, GITRL, ICOS, GITR) and three co-inhibitory (TIM-3, CTLA-4, PD-L1) soluble checkpoints were significantly lower in the BC patients vs. controls (p<0.021-p<0.0001; and p<0.008-p<0.00001, respectively). …”
  20. 64620

    The main rebound results are robust to different fertility assumptions. by Dean Spears (459329)

    Published 2024
    “…In all scenarios, after 2100, TFR increases or decreases at the “medium” convergence speed of 3% per five-year period until reaching the long-run level or 2200, whichever is earlier. …”